AAVs are small, non-enveloped, single-stranded DNA viruses that were discovered in the 1960s as contaminants of adenovirus preparations. They induce limited host immune responses and are not associated with any known diseases. However, they have been found to efficiently deliver DNA cargo to many tissues in multiple animal species. Thus, AAV vectors are widely used as gene transfer tools in basic research and in translational and clinical gene therapy. Their higher use has increased the demand for AAV manufacturing, in terms of both the quality and quantity of the preparation.

Generating clinical good manufacturing practice (GMP)-grade adeno-associated virus vectors requires purification strategies that produce high-purity vectors with a good safety and efficacy profile. Currently, most reported purification schemes are serotype-dependent, necessitating method development for each AAV gene therapy product.

To safeguard the critical role of AAV vector purification in biopharmaceutical and vaccine production and ensure the safety, efficacy, and compliance of gene therapy products and virus-vector-based vaccines, CD Bioparticles now offers researchers AAV Affinity Agarose Resins. These resins efficiently and scalably purifies diverse AAV vector subtypes, including AAV2, AAV5, AAV8, and AAV9, which are used in gene therapy and vaccine production. These high-performance resins deliver exceptional dynamic binding capacity, even at short residence times.

CD Bioparticles' AAV affinity agarose resin is an affinity chromatography medium engineered to purify AAV particles. It uses a highly cross-linked agarose matrix and animal-free ligands that have a strong affinity for multiple AAV serotypes. The resin is suitable for AAV purification across scales, from research to industrial production.

These new affinity resins offer multiple advantages. For example, they exhibit outstanding alkaline stability and reusability. Their performance remains unaffected even after multiple cycles of conventional CIP washing using 0.1–0.5 M NaOH. The resins have been validated for reuse over 20 cycles. This durability ensures an extended resin lifespan, reduced downtime, and lower per-batch costs. These resins can streamline purification workflows and significantly enhance the cost-effectiveness of bioprocesses overall, making them an ideal choice for sustainable, cost-efficient manufacturing.

CD Bioparticles' new portfolio of AAV affinity resins is fully compatible with standard bioprocess columns and flow rates. These resins maintain high impurity removal rates, ensuring effective host cell protein (HCP) and residual DNA depletion, even after 20 purification cycles. In addition, the resins can achieve high dynamic binding capacity within short residence times, enabling the efficient processing of pre-concentrated feedstock or the direct capture of target molecules from clarified harvests.

For more information about the Alkali-Tolerant AAV Affinity Agarose Resins or to request a quote, please visit https://www.cd-bioparticles.com/products/alkali-tolerant-aav-affinity-resins-for-biopharmaceutical-purification.html.

About CD Bioparticles

CD Bioparticles is a leading manufacturer and supplier of various nanoparticles, microparticles, and coatings for R&D as well as commercialization across different application areas, including in vitro diagnostics, biochemistry, cellular analysis, cell separation, and immunoassay. The company also offers various custom services, including chemical surface-functionalization, fluorescent modification, antibody immobilization, as well as nucleic acid and oligo conjugation to meet client specifications.